The Heart Foundation Pharmaceutical Roundtable (the Roundtable) brings together members of leading pharmaceutical companies to help improve the cardiovascular health of Australians. Since its inception, the Roundtable has contributed about $4 million towards advancing cardiovascular research.
This collaboration also offers members a unique opportunity to participate in and develop new evidence based consumer health education and prevention projects together with the Heart Foundation, with a particular focus on Quality Use of Medicines (QUM) and adherence.
The Heart Foundation acknowledges the Roundtable as a unique opportunity to provide sector leadership and a productive alliance, delivering mutual benefits to the member companies and the Heart Foundation as well as improved health outcomes for the public.
The operating principles of the Roundtable are based on:
- achieving and maintaining trust and
- respect for the Heart Foundation’s independence.
The Heart Foundation Research Program operates independently of the Pharmaceutical Roundtable. The Research Program allocates funding using an independent peer review process, where external committees review and rank all the applications we receive for research funding every year. These committees are made up of experienced researchers and academics from around the country who are experts in cardiovascular disease. This process ensures the Heart Foundation operates in a fair and transparent manner, only funding the highest quality research applications we receive.
For a full list on the current Pharmaceutical Roundtable members, click here
To view the Roundtable’s work on Quality use of Medicines (QUM), click here
The Roundtable is facilitated by the Heart Foundation Pharmaceutical Roundtable Charter, Roundtable Charter Download
To read more about the Roundtable, download the latest Pharmaceutical Roundtable flyer Download
For any further information, please contact the Heart Foundation on (03) 9321 1534.